Showing results (331-340 of 831) with videos related to

Sort By:
Pageof 84
Cancer|June 26, 2010
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemiaTait D Shanafelt, Kari G Rabe, Neil E Kay, et al.
Blood|August 16, 2003
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cellsJoya Chandra, Jennifer Hackbarth, Son Le, et al.
Journal of Oncology Practice|March 26, 2015
Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levelsTait D Shanafelt, Bijan J Borah, Heidi D Finnes, et al.
Experimental Hematology|May 7, 2022
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemiaCamilia M Soof, Tanya M Spektor, Sameer A Parikh, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
British Journal of Haematology|February 6, 2016
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experienceDaniel L Van Dyke, Lillian Werner, Laura Z Rassenti, et al.
British Journal of Haematology|June 18, 2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaFabio P S Santos, Hagop Kantarjian, Carmen Fava, et al.
Cancer|September 7, 2006
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|March 8, 2007
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureHagop Kantarjian, Susan O'Brien, Moshe Talpaz, et al.
Blood|July 2, 2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsElias Jabbour, Daniel Jones, Hagop M Kantarjian, et al.
Pageof 84